Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

ACEP Policy on Low-Dose Ketamine

By Daniel Freess, MD, FACEP; and Elizabeth Schiller, MD, FACEP | on January 30, 2018 | 0 Comment
Uncategorized
  • Tweet
  • Email
Print-Friendly Version

A recent ACEP policy reviewed the safety and efficacy of ketamine for emergency analgesic use. The policy recommends dosing and monitoring protocols similar to other parenteral analgesics. Studies looking at low-dose ketamine (LDK) (also referred to as subdissociative-dose ketamine) support a trend toward improved analgesia compared to opiates with a similar or better side effect profile. Additionally, LDK augments the analgesia attained by patients who have already been given an opioid and reduces the need for re-dosing of opioid medications.

You Might Also Like
  • Low-Dose Ketamine Emerges as Effective Opioid Alternative
  • Fentanyl Versus Ketamine for Intranasal Pain Relief
  • ACEP Adopts Opioid Clinical Policy Recommendation addresses critical issues in the prescribing of opioids for adult patients

LDK has been shown to have a functionally equivalent efficacy to morphine for short-term analgesia in the emergency setting. Recommended dosing is 0.1–0.3 mg/kg as an IV infusion over 15 minutes. The predictability and dosing are less clear for the intramuscular (IM) route, though many physicians have reported IM delivery with similar efficacy.

At low doses, ketamine acts as an analgesic rather than anesthetic. Use of LDK should not require intensive monitoring and overall has less respiratory and hemodynamic effects when compared to opioids. According to the ACEP policy, LDK is safe for non-monitored use when dosed according to the aforementioned protocols. It may be selected as a first-line agent over opioid agents for some patients, particularly those with chronic opioid use, contraindications to opioids, or hypotension secondary to trauma or sepsis. Ketamine is contraindicated in infants younger than three months, but there has been no evidence to suggest that LDK should be avoided in or results in exacerbation of psychosis in patients with mental illness.

ACEP recommends disclosure of LDK side effects to patients prior to administration. Patients may experience nausea, dizziness, and dysphoria, which are often brief and typically mild. The frequency of these side effects was reduced when LDK was given as a short infusion rather than a bolus. Emergence reactions have not been associated with LDK when used in the typical dosing range.

So the next time the nurse asks you for an order for more morphine, consider LDK. There is a good chance your patient will thank you and will require less opioids during the emergency department stay.

Resources for Further Reading

  1. American College of Emergency Physicians. Optimizing the treatment of acute pain in the emergency department [policy statement]. Approved April 2017.
  2. Ahern TL, Herring AA, Miller S, et al. Low-dose ketamine infusion for emergency department patients with severe pain. Pain Med. 2015;16(7):1402-1409.
  3. Beaudoin FL, Lin C, Guan W, et al. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014;21(11):1193-1202.
  4. Bowers KJ, McAllister KB, Ray M, et al. Ketamine as an adjunct to opioids for acute pain in the emergency department: a randomized controlled trial. Acad Emerg Med. 2017;24(6):676-685.
  5. Miller JP, Schauer SG, Ganem VJ, et al. Low-dose ketamine vs morphine for acute pain in the ED: a randomized controlled trial. Am J Emerg Med. 2015;33(3):402-408.
  6. Motov S, Mai M, Pushkar I, et al. A prospective randomized, double-dummy trial comparing IV push dose of low dose ketamine to short infusion of low dose ketamine for treatment of pain in the ED. Am J Emerg Med. 2017;35(8):1095-1100.
  7. Richards JR, Rockford RE. Low-dose ketamine analgesia: patient and physician experience in the ED. Am J Emerg Med. 2013;31(2):390-394.
  8. Smith RK, Messman A, Wilburn J. Low-dose ketamine emerges as effective opioid alternative. ACEP Now. August 2017. Accessed Sept. 15, 2017.

Pages: 1 2 | Single Page

Current Issue

ACEP Now May 03

Read More

No Responses to “ACEP Policy on Low-Dose Ketamine”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603